Omniscope is involved in many projects...
This project, called EPIVINF, is a Horizon Europe - Health project, funded by the European Commission. EPIVINF is a 60-month project with a total budget of EUR 6.9 million and started on the 1st of September 2022. The budget allocated to Omniscope is EUR 1.5 million.
The EPIVINF project aims to study the epigenetic regulation of host factors critical for immune control and neurological health during acute viral infections.
HIV and SARS-CoV-2 will be studied due to their shared features and impact on millions of people. The project hypothesizes that understanding epigenetic profiles, immune responses, and epigenetic control mechanisms in these infections will provide insights into how different individuals react and how different infections share similar mechanisms.
The project will use cutting-edge epigenetic analyses, immune monitoring tools, disease-relevant animal models, and samples from unique human vaccine trials to gain a deep understanding of viral infections' impact on the immune phenotype, potentially leading to novel therapeutic interventions. Patient follow-up will be extensive, identifying factors predisposing to different clinical symptoms and disease progression.
Omniscope is a partner in all work packages and leads work pack 3, focusing on the epigenetic regulation of the response to HIV and SARS-CoV-2 vaccination. Omniscope will conduct single-cell transcriptomics analyses in isolated T and B cell populations from infected individuals, and work on the BCR and TCR repertoire evolution upon vaccination. Further Omniscope will provide insights into the optimal timing for immune receptor analyses and will contribute to work pack 5 by providing cleaned and curated 10X transcriptomics data, and TCR / BCR repertoire data for suitable database development. The project aims to generate extensive data on viral infections and identify relevant epigenetic biomarkers to improve therapeutic interventions.
Leverage single-molecule resolution for deep, quantitative, and cost-efficient profiling of T and B cell repertoires.
Determine which patients are likely to benefit from your drug.
Leverage single-molecule resolution for deep, quantitative, and cost-efficient profiling of T and B cell repertoires.
Discover patient populations that are at risk of adverse reactions with your drug.
Experience the power of single-cellular resolution for deep, quantitative, and qualitative profiling of T and B cell repertoires.
Accelerate your therapy development by identifying and testing (in silico & in vitro) novel candidates for advanced cell therapy.
This project, called EPIVINF, is a Horizon Europe - Health project, funded by the European Commission. EPIVINF is a 60-month project with a total budget of EUR 6.9 million and started on the 1st of September 2022. The budget allocated to Omniscope is EUR 1.5 million.
The EPIVINF project aims to study the epigenetic regulation of host factors critical for immune control and neurological health during acute viral infections.
HIV and SARS-CoV-2 will be studied due to their shared features and impact on millions of people. The project hypothesizes that understanding epigenetic profiles, immune responses, and epigenetic control mechanisms in these infections will provide insights into how different individuals react and how different infections share similar mechanisms.
The project will use cutting-edge epigenetic analyses, immune monitoring tools, disease-relevant animal models, and samples from unique human vaccine trials to gain a deep understanding of viral infections' impact on the immune phenotype, potentially leading to novel therapeutic interventions. Patient follow-up will be extensive, identifying factors predisposing to different clinical symptoms and disease progression.
Omniscope is a partner in all work packages and leads work pack 3, focusing on the epigenetic regulation of the response to HIV and SARS-CoV-2 vaccination. Omniscope will conduct single-cell transcriptomics analyses in isolated T and B cell populations from infected individuals, and work on the BCR and TCR repertoire evolution upon vaccination. Further Omniscope will provide insights into the optimal timing for immune receptor analyses and will contribute to work pack 5 by providing cleaned and curated 10X transcriptomics data, and TCR / BCR repertoire data for suitable database development. The project aims to generate extensive data on viral infections and identify relevant epigenetic biomarkers to improve therapeutic interventions.
This project, called SIGNATURE, is part of the Marie Skłodowska-Curie Actions Programme and the Horizon Europe program, the European Union's R&D&I plan. SIGNATURE is a 48-month project with a budget of EUR 2.6 Million, starting in 2023. Its network will train enterprising, innovative, and resilient doctoral students, capable of facing current and future challenges and turning knowledge and ideas into products and services for economic and social benefit.
Autoimmune disorders are highlyImmune-mediated disorders and highly heterogeneous entities for which the mechanisms of disease progression and therapeutic responses are only recently beginning to be understood. The patterns of transcriptome are the reflection of distinct cell types that are involved in the development of the disease process.
The project is based on a unique ongoing platform of clinical groups across Europe and specialists in cell and molecular profiling, imaging analyses, single cell sequencing and analysis. It will have the availability to existing clinical studies and clinical trials, as well as prospective studies of which new data will be produced.
Further a specialized training program will be developed where students will be able to visualize the overall work from design to analysis of the data, and will engage in the unique multi-disciplinariry of this platform.
Omniscope is one of the associated partners to SIGNATURE and will be involved in delivering a 10-day course (2 ECTS) on single-cell data generation and analysis, and a 1-day workshop about founding a biotech company (0.5 ECTS).
Belgium:
France:
Germany:
Italy:
Netherlands:
Spain:
